Cerca Biotech

The final installment in our #ThrowbackThursday series. Back in March, at our #Expert meeting in Milan, we discussed the future for #BreastCancer #Diagnostics and why #MammaTyper is the tool of choice. With published evidence to support its performance, the implementation of MammaTyper across Europe is the goal. Watch the 📺 link below in the comments.

🤩 #ThrowbackThursday The second in our Thursday reflections series and today we are looking back to our #Expert Meeting in March 2024. Together in Milan, we discussed why #MammaTyper is the solution to drive improvements in the diagnostic pathway for #BreastCancer #Diagnostics #Innovation Dr Simona Frezzini Prof Daniele Generali. Head over to our YouTube channel to view the 📺 Link in the comments 👇🏻

Nearly time for #SABCS24 - great to see Paolo Tarantino sharing the Top 10 #Abstracts. Looking forward to hearing the great research to be shared 📚🔬 #Diagnostics #BreastCancer

🤩 #ThrowbackThursday The first in our Thursday reflections series and today we are looking back to our Expert Meeting in March 2024. Together in Milan, we discussed the use of #MammaTyper and how the test can be used to improve the diagnostic pathway for #BreastCancer #Diagnostics #Innovation Dr Simona Frezzini Prof Daniele Generali. Head over to our YouTube channel to view the 📺 Link in the comments 👇🏻

📚 Happy to share recently published data from the Archives of Pathology and Laboratory Medicine with Ximena Báez Navarro et al looking at whether mRNA expression quantified via RT-qPCR could serve as a valuable complementary and more objective method to identify #HER2Low #Breast Cancers. College of American Pathologists (CAP) 🔬 The findings indicate a strong agreement between mRNA expression as quantified by RT-qPCR and HER2 IHC scores, although there was still a substantial proportion of discordant HER2 results between both methods. Future large-scale studies comprising clinical outcome are needed to determine the added (or even superior) value of mRNA quantification in nonamplified HER2 BC.” ⬇ Link to the Open Access paper in the comments #Pathology #Laboratory #ExpertResearch

💗 As #BreastCancerAwareness Month 2024 comes to a close, it is important to remember that it doesn't end here! MammaTyper® applies 21st century techniques to breast cancer subtyping, ensuring that every tissue sample is tested reliably, accurately, and quickly. 🔽 Scroll through the #Expert Quotes from Prof @JohnBartlett, Prof Abeer Shaaban, Dr Liz O’Riordan and Prof Emad Rakha. #Diagnostics #BreastCancer #Innovation

🌟🔬For the final video in our #Expert series to support #BreastCancerAwareness month, we hear from Professor Abeer Shaaban discussing the concordance study with #MammaTyper and IHC. Using core biopsy samples, her study showed excellent concordance and the data was published in Wiley In Research Histology. ⬇ Link in comments 📺 Watch the full video here https://lnkd.in/eiSnUzUa

💗 For #BreastCancerAwareness month we are discussing the development of new diagnostic technologies, and their use alongside existing processes. Professor Emad Rakha spoke to us about #BreastCancer subtyping and the way forward. 📺 Watch the video here https://lnkd.in/eVJ3swQS #Innovation #MammaTyper #Diagnostics

For #BreastCancerAwareness month we spoke to a range of experts to discuss progress in diagnosis, treatment and management of breast cancer. In our latest video, Professor Abeer Shaaban talks about the importance of precision medicine and individualising treatment so that each patient receives the best option for their tumour. #Diagnostics #Innovation #MammaTyper 📺 Watch the video here https://lnkd.in/eWcD7jBH

🗞 Great news to share from Wiley In Research that Prof Abeer Shaaban Anthony Kong and Daniel Kearns CSci FIBMS CBiol FRSB FRSC FRSM work on the Concordance between ER, PR, Ki67, and HER2‐low expression in breast cancer by MammaTyper RT‐qPCR and immunohistochemistry has received over 1,000 views 🎉 Link to the paper in the comments ⬇ #ViewsMilestone #Pathology #Innovation